The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28280261 |
84 |
Non-kinase targets of protein kinase inhibitors. |
The University Of Sydney |
| 27474927 |
76 |
Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors. |
Paris-Sud University |
| 26771245 |
7 |
Recent developments of 2-aminothiazoles in medicinal chemistry. |
Sree Chaitanya College |
| 26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). |
Icahn School Of Medicine At Mount Sinai |
| 25899335 |
1 |
Synthesis and identification of unprecedented selective inhibitors of CK1e. |
Instituto Universitario De Bio-Org£Nica Antonio Gonz£Lez (Iubo-Ag) |
| 25191940 |
48 |
Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1d ande with nanomolar inhibitory activity on cancer cell proliferation. |
Ulm University Hospital |
| 23919824 |
18 |
Ligand-protein interactions of selective casein kinase 1d inhibitors. |
Pfizer |
| 22749643 |
69 |
Structure-based optimization of oxadiazole-based GSK-3 inhibitors. |
Technische Universit£T Darmstadt |
| 22944772 |
15 |
Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. |
TBA |
| 22726925 |
216 |
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease. |
Cellzome |
| 23106386 |
4 |
Structural basis for the potent and selective inhibition of casein kinase 1 epsilon. |
Amgen |
| 22533818 |
84 |
Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3a. |
Technische Universit£T Darmstadt |
| 18183025 |
12060 |
A quantitative analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
| 18077363 |
314 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
University Of Oxford |
| 22168824 |
4 |
Structural basis for the interaction between casein kinase 1 delta and a potent and selective inhibitor. |
Amgen |
| 22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
| 21807510 |
31 |
Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. |
Technische Universit£T Darmstadt |
| 21375264 |
77 |
Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors |
Roche Palo Alto |
| 19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). |
Ambit Biosciences |
| 19950901 |
23 |
Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. |
Roche Palo Alto |
| 19837585 |
46 |
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). |
National Human Genome Research Institute |
| 19591487 |
38 |
3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta. |
Eberhard-Karls University |
| 16366598 |
51 |
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. |
Johnson & Johnson Pharmaceutical Research And Development |
| 15999992 |
25 |
Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors. |
Johnson & Johnson Pharmaceutical Research And Development |
| 15711537 |
653 |
A small molecule-kinase interaction map for clinical kinase inhibitors. |
Ambit Biosciences |
| 18251489 |
9 |
Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. |
Mclean Hospital |
Search and Browse
